IPR decision: Jan. 20, 2022

AIA Review #	Filing Date	Institution Date	Petitioner	Patent	Respondent	Final Written Decision
IPR2020-01053	06/05/2020	12/09/2020	Slayback Pharma LLC	9815827	Sumitomo Dainippon Pharma Co., Ltd.	All Challenged Claims Unpatentable

 

US 9,815,827 (Sumitomo Dainippon Pharma. Co., Ltd; Exp: 02/20/2024):

1. A method for treating schizophrenia in a patient without a clinically significant weight gain, comprising: administering orally to the patient (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof at a dose of from 20 to 120 mg/day such that the patient does not experience a clinically significant weight gain.

 

8. A method for treating manic depressive psychosis in a patient without a clinically significant weight gain, comprising: administering orally to the patient (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmet- hyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof at a dose of from 20 to 120 mg/day such that the patient does not experience a clinically significant weight gain.

 

25. A method of treating a patient with an antipsychotic without a clinically significant weight gain in the patient, comprising: orally administering the antipsychotic to the patient once daily at a dose of from 20 to 120 mg such that the patient does not experience a clinically significant weight gain, wherein the antipsychotic is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmet- hyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof.

 

40. A method of treating a patient with an antipsychotic without a clinically significant weight gain, comprising: orally administering once daily to the patient a pharmaceutical composition comprising 20 to 120 mg of (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinyl- methyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof as a sole active ingredient such that the patient does not experience a clinically significant weight gain.

 

56. A method of treating a patient with an antipsychotic without a weight gain, comprising: orally administering once daily to the patient a pharmaceutical composition comprising 20 to 120 mg of (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmet- hyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof as a sole active ingredient such that the patient does not experience a weight gain.